Newsroom
News from our partners
This newsroom will share the latest information about anything related to narcolepsy, idiopathic hypersomnia, and sleep together with press releases from us and our partners.
09/27/24
CENTESSA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 Agonist, at the 27th Congress of the European Sleep Research Society
09/25/24
AVADEL Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate)
09/03/24
PWN4PWN Welcomes Kyle Chastain as New Treasurer on Board of Directors
07/31/24
AVADEL Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Older news.
06/03/24
TAKEDA Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
02/21/24
Harmony Biosciences U.S. Food and Drug Administration has granted priority review for Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy
01/24/24
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
